The event, which has feature presentations by leading clinicians as well as key members of the OSE Immunotherapeutics management team, has provided an update on : • The Company’s strategy to build a leading portfolio of best- and first-in-class cancer immunotherapies. • OSE’s goal to position Tedopi® as a new standard of care in non-small […]
Read more
